welcome to oneEDSvoice- a positively charged Ehlers Danlos Syndrome community.
- join today!
Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
study id #: NCT00190411
condition: Ehlers-danlos syndrome, type iv, autosomal dominant Chromosome 2q31.2 deletion syndrome
Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed that arteries are thin and overloaded in this patients. We test the protective effect of celiprolol on cardiovascular events in a 5 years, randomized, PROBE design
intervention: Drug: celiprolol celiprolol Other Names: - celiprolol? Dose ranging 100 to 400 mg, dose adaptation - every 6 months by increment of 100 mg, based on tolerance Drug: Control Untreated controls excluding betablockers
- Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010 Oct 30;376(9751):1476-84. doi: 10.1016/S0140-6736(10)60960-9. Epub 2010 Sep 7. Erratum in: Lancet. 2016 Aug 6;388(10044):564. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.
start date: October 2003
estimated completion: April 2011
last updated: January 16, 2013
phase of development: Phase 4
size / enrollment: 54
study design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
study description: 100 patients with verified EDS-IV syndrome are included. Patients are randomized to either celiprolol (50 to 400 mg BID)or no treatment. Patients who are not randomized enter a longitudinal survey of events. The hypothesis is a 50% reduction in the occurrence of cardiovascular events under treatment, assessed by a blinded, independent events committee.
- reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-up [ Time Frame: during de study ] reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-up
- Tolerance, effect of drug on arterial parameters : diameter, IMT, stiffness. [ Time Frame: during the study ] Tolerance, effect of drug on arterial parameters : diameter, IMT, stiffness.
inclusion criteria: Proven disease, No betablocker at inclusion if previous CV event
exclusion criteria: Criteria of not inclusion for the RIGHTEOUS group: Patient having already presented an arterial break or a dissection and treated(handled) by bétâ-blocking(surrounding). Against indication in the use of CELIPROLOL: Unchecked cardiac insufficiency by the treatment cardiogenic shock BAV of 2nd and 3rd not sailed degrees angor of Prinzmetal disease of the sine bradycardia pheochromocytoma untreated low blood pressure sentimentality in the CELIPROLOL Antecedent of anaphylactic reaction myasthenia treatment by FLOCTAFENINE ( Idarac), Sultopride ( interactions ) In these two cases, the patient can be included in the group followed by troop.
expertly curated content related to this topic
Ehlers-Danlos Syndrome (Two Cases)Case 1 Ehlers-Danlos Syndrome (X-linked ...
Ehlers-Danlos SyndromeBitterly trying to find some solace in p...
Skin Ultrastructural Clues on the Impact of Ehlers-Danlos Syndrome in WomenEhlers-Danlos syndrome is heterogeneous ...
EDS: It Takes a Village – A Physical Therapist’s Role in an Integrative Approachhttps://www.youtube.com/watch?v=ml3R8Cpt...
21st Century Ehlers-Danlos Syndrome (EDS) Sourcebook: Clinical Data for Patients, Families, and Physicians – C...This comprehensive ebook provides author...